Published in Hepatitis Weekly, January 15th, 2007
Following an agreement earlier this year, Tibotec and Vertex are collaborating to develop telaprevir in Europe, South America, Australia, the Middle East, and selected Asian countries.
In accordance with the PROVE 1 study design, an interim safety and antiviral activity analysis has been conducted and the data have been reviewed by the independent data monitoring committee overseeing the trial. A total...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.